María Teresa Herranz

María Teresa Herranz

Auto-generated profile, based on publicly available information

María Teresa Herranz

18Department of Internal Medicine, Hospital J.M. Morales Meseguer, Murcia, Spain

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1994 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
MHM. Teresa Herranz
M. Teresa Herranz
GRGilles Rivier
Gilles Rivier
MKMunther A. Khamashta
Munther A. Khamashta
KBKlaus U. Blaser
Klaus U. Blaser
GHGraham R. V. Hughes
Graham R. V. Hughes
Objective. To determine whether the occurrence of seizures is correlated with the presence of serum antiphospholipid antibodies (aPL) in systemic lupus erythematosus (SLE) patients.Methods. The study included 221 unselected patients with SLE. Of these, 21 patients with epileptic seizures not attributed to any cause other than SLE were identified. Epilepsy was diagnosed by clinical history and electroencephalography. Blood samples were tested for the presence of antibodies to cardiolipin (aCL, IgG and IgM isotypes) and lupus anticoagulant (LAC).Results. LAC was detected in 43.8% of the patients with epilepsy and in 20.8% of controls (P = 0.057). A statistically significant association was found between moderate‐to‐high titers of IgG aCL and the presence of seizures (P = 0.02). Brain computed tomography and/or magnetic resonance imaging scanning was performed in 14 patients. All patients with abnormal features found on these tests had positive aPL (P = 0.03). Nine patients (42.9%) had at least 1 of the classic features associated with the aPL syndrome.Conclusion. We confirmed that epilepsy as a primary neuropsychiatric event is significantly associated with moderate‐to‐high titers of IgG aCL in SLE patients. Our results suggest that aPL could have a role in the etiopathogenesis of epilepsy in SLE.

21 July 2011 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
RTR. Teruel
R. Teruel
CPCarlos Pérez-Sánchez
Carlos Pérez-Sánchez
JCJ. Corral
J. Corral
MHM. T. Herranz
M. T. Herranz
VPV. Pérez‐Andreu
V. Pérez‐Andreu
CMConstantino Martinez
Constantino Martinez
Summary. Background: Tissue factor (TF) is the main initiator of the coagulation cascade and elements that may upregulate its expression might provoke thrombotic events. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) are autoimmune diseases characterized by a high TF expression in monocytes. Objectives: To examine the role of microRNAs (miRNAs) in TF expression and to evaluate their levels in SLE and APS patients. Methods: An in silico search was performed to find potential putative binding sites of miRNAs in TF mRNA. In vitro validation was performed transfecting cells expressing TF (THP‐1 and MDA‐MB‐231) with oligonucleotide miRNA precursors and inhibitors. Additionally, reporter assays were performed to test for the binding of miR‐20a to TF mRNA. Levels of miRNAs and TF were measured by quantitative (qRT‐PCR) in patients with APS and SLE. Results: Overexpression of miRNA precursors, but not inhibitors, of two of the members of cluster miR‐17∼92, for example miR‐19b and miR‐20a, in cells expressing TF decreased TF mRNA, protein levels, and procoagulant activity between 30% and 60%. Reporter assays showed that miR‐20a binds to TF mRNA. Finally, we measured levels of miR‐19b and miR‐20a in monocytes from patients with APS and SLE and observed significantly lower miRNAs levels in comparison with healthy subjects inversely correlated with the levels of TF. Conclusions: Down‐regulation of miR‐19b and miR‐20a observed in patients with SLE and APS could contribute to increased TF expression and thus provoke the hypercoagulable state characteristic of these patients.

1 September 1998 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JRJ M Ródenas
J M Ródenas
MHM T Herranz
M T Herranz
JTJesus Tercedor-Sanchez
Jesus Tercedor-Sanchez

1 April 1994 in Lupus
Verified
Journal Article
Closed access
GRGilles Rivier
Gilles Rivier
MHM. Teresa Herranz
M. Teresa Herranz
MKMunther A. Khamashta
Munther A. Khamashta
GHGraham R.V. Hughes
Graham R.V. Hughes
To assess retrospectively three antithrombotic treatments in the secondary prevention of thrombosis in the antiphospholipid syndrome (APS), 23 patients (six systemic lupus erythematosus, seven lupus-like disease and 10 primary antiphospholipid syndrome) were included in this study. Treatments assessed were: (1) aspirin 75 mg daily, (2) warfarin (international normalised ratios (INRs) 2.0-2.9) ± aspirin 75 mg daily, and (3) warfarin (INRs > 2.9) ± aspirin 75 mg daily. Where patients had received two or three of these treatments successively, the periods of time on each treatment were added and the number of patients with recurrence(s) on each treatment were compared by Fisher's exact probability test. 'High' anticoagulation (INRs > 2.9) ± aspirin 75 mg daily was more effective than aspirin 75 mg daily in preventing further thromboembolic events (P = 0.0053). In addition, when comparing 'high' anticoagulation ± aspirin 75 mg daily versus 'low' anticoagulation (INRs 2.0-2.9) ± aspirin 75 mg daily, there was a trend in favour of 'high' anticoagulation (P = 0.066). No statistically significant difference could be demonstrated when comparing 'low' anticoagulation ± aspirin 75 mg daily with aspirin 75 mg daily (P = 0.092). These results suggest that aggressive anticoagulation with or without low-dose aspirin is effective in preventing further thromboembolic events in APS.

1 June 1997 in American Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
JRJosé M. Ródenas
José M. Ródenas
MDMiguel Delgado-Rodríguez
Miguel Delgado-Rodríguez
CFConcepción Fariñas-Álvarez
Concepción Fariñas-Álvarez
MHMaría T. Herranz
María T. Herranz
SSSalvio Serrano
Salvio Serrano
The main objective of this study was to assess whether cutaneous malignant melanoma (CMM) shows a stronger relation with the melanocytic nevi count at the site where CMM was diagnosed than with the melanocytic nevi count at other sites, stratifying by histologic CMM type, in a southern Mediterranean population. Cases and controls were selected from a population in southern Spain in 1988–1993. The study population included 116 incident cases with non-familial CMM (International Classification of Diseases 9th Revision (ICD-9) code 172), and 116 controls matched 1: 1 for sex and age (±4 years). Data were collected by personal interview, and melanocytic nevi were counted over the entire body surface by clinical skin examination performed by a dermatologist. Crude and multiple risk factor-adjusted odds ratios and 95% confidence intervals were computed by conditional logistic regression analysis. After adjustment by skin type, unexposed skin color, and sun exposure, CMM was found to occur significantly more frequently in individuals with a high number of melanocytic nevi at the same site where CMM originated (odds ratio (OR) for >8 nevi = 12.0, 95% confidence interval (CI) 1.3–108.2). The ability to predict the number of melanocytic nevi on different anatomic sites on CMM, but exCIuding the CMM cases on each corresponding site, was also examined. A significant trend wrth the number of nevi on the anterior surface of thighs was found (OR for >4 nevi = 4.5, 95% CI 1.4–14.9). Melanocytic nevi count on the melanoma site was the variable most CIosely related to superficial spreading melanoma subtype (SSM) (OR for >8 nevi = 82.19, 95% CI 2.72–2,454). On the other hand, the number of melanocytic nevi on the melanoma site was unrelated to risk of CMM subtypes other than SSM. These results support the hypothesis that nevi are an important risk factor for melanoma, especially SSM, in populations with a darker ethnic background. Am J Epidemiol 1997;145:1020-9.

2 August 2016 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
GRGuillermo Ruiz-Irastorza
Guillermo Ruiz-Irastorza
MGM Garcia
M Garcia
GEG Espinosa
G Espinosa
LCL Caminal
L Caminal
FMF Mitjavila
F Mitjavila
LPL Pallarés
L Pallarés
Aim To study the influence of prednisone dose during the first month after systemic lupus erythematosus (SLE) diagnosis (prednisone-1) on glucocorticoid burden during the subsequent 11 months (prednisone-2–12). Methods 223 patients from the Registro Español de Lupus Eritematoso Sistémico inception cohort were studied. The cumulative dose of prednisone-1 and prednisone-2–12 were calculated and recoded into a four-level categorical variable: no prednisone, low dose (up to 7.5 mg/day), medium dose (up to 30 mg/day) and high dose (over 30 mg/day). The association between the cumulative prednisone-1 and prednisone-2–12 doses was tested. We analysed whether the four-level prednisone-1 categorical variable was an independent predictor of an average dose >7.5 mg/day of prednisone-2–12. Adjusting variables included age, immunosuppressives, antimalarials, methyl-prednisolone pulses, lupus nephritis and baseline SLE Disease Activity Index (SLEDAI). Results Within the first month, 113 patients (51%) did not receive any prednisone, 24 patients (11%) received average low doses, 46 patients (21%) received medium doses and 40 patients (18%) received high doses. There was a strong association between prednisone-1 and prednisone-2–12 dose categories (p<0.001). The cumulative prednisone-1 dose was directly associated with the cumulative prednisone-2–12 dose (p7.5 mg/day, while patients receiving low-dose prednisone-1 were not (adjusted OR 1.4, 95% CI 0. 0.38 to 5.2). If the analysis was restricted to the 158 patients with a baseline SLEDAI of ≥6, the model did not change. Conclusion The dose of prednisone during the first month after the diagnosis of SLE is an independent predictor of prednisone burden during the following 11 months.